A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

The anti-ErbB2 antibodies trastuzumab and pertuzumab in combination have recently been approved for the treatment of patients with ErbB2-positive metastatic breast cancer. Pertuzumab, which binds to ErbB2 near the center of domain II, and trastuzumab, which binds to the juxtamembrane region of ErbB2...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncogenesis
Glavni autori: Meng, Y, Zheng, L, Yang, Y, Wang, H, Dong, J, Wang, C, Zhang, Y, Yu, X, Wang, L, Xia, T, Zhang, D, Guo, Y, Li, B
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815051/
https://ncbi.nlm.nih.gov/pubmed/26999718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2016.25
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items